Back to Results

Inhibitor Therapeutics Inc (INTI)

Featured in Overvalued Stocks

Inhibitor Therapeutics Inc. (OTC Markets: INTI) is a healthcare company focused on pharmaceutical development. The company works on therapies aimed at patients with certain cancers and non-cancerous proliferation disorders in the United States, with a particular emphasis on prostate and lung cancer programs using itraconazole. Its clinical work has included a positive Phase 2b trial of SUBA-Itraconazole for basal cell carcinoma nevus syndrome. The company was previously known as HedgePath Pharmaceuticals, Inc. and adopted its current name in August 2019. Founded in 1992, Inhibitor Therapeutics is based in Tampa, Florida.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-INTI
$0.039
-49.3% Downside
Overvalued
—
—
—
Weak
—
—
—
0.0%
August 13, 2026
-4.0x
-6.8x
—
13.478 M
12.236 M
0.4%
44.9%
-59.5
—
90.4%
Valuation • Fair Value

Inhibitor Therapeutics Inc (OTC-INTI) Fair Value by Valuation Model

Compare the primary fair value estimate for Inhibitor Therapeutics Inc (OTC-INTI) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.039

Estimated downside of 49.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.039

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Inhibitor Therapeutics Inc (OTC-INTI) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Inhibitor Therapeutics Inc (OTC-INTI)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Inhibitor Therapeutics Inc (OTC-INTI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Inhibitor Therapeutics Inc (OTC-INTI)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-59.5

Lower score that deserves closer risk review.

FCF / Net Income

90.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Inhibitor Therapeutics Inc (OTC-INTI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Inhibitor Therapeutics Inc (OTC-INTI)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 13, 2026

Days to Earnings

23

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Inhibitor Therapeutics Inc (OTC-INTI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Inhibitor Therapeutics Inc (OTC-INTI) Stock Forecast & Technical Outlook

Review Inhibitor Therapeutics Inc (OTC-INTI) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Inhibitor Therapeutics Inc (OTC-INTI) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Inhibitor Therapeutics Inc (OTC-INTI) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Inhibitor Therapeutics Inc (OTC-INTI) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Inhibitor Therapeutics Inc (OTC-INTI) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Inhibitor Therapeutics Inc (OTC-INTI) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Inhibitor Therapeutics Inc (OTC-INTI)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Inhibitor Therapeutics Inc (OTC-INTI) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Inhibitor Therapeutics Inc (OTC-INTI) Stock FAQ

Quick answers about Inhibitor Therapeutics Inc (OTC-INTI) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.039
Estimated downside 49.3%
Valuation Rating
Overvalued
Estimated downside of 49.3%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Inhibitor Therapeutics Inc (OTC-INTI) is $0.039. This implies an estimated downside of 49.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 49.3% versus the current market price.

An analyst price target for Inhibitor Therapeutics Inc (OTC-INTI) is not currently available in the latest data file.

The current financial health read for Inhibitor Therapeutics Inc (OTC-INTI) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Inhibitor Therapeutics Inc (OTC-INTI) is August 13, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Inhibitor Therapeutics Inc (OTC-INTI) is -4.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Inhibitor Therapeutics Inc is 13.478 M.

The current enterprise value listed for Inhibitor Therapeutics Inc is 12.236 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Inhibitor Therapeutics Inc is OTC-INTI, and the stock is listed on OTC Markets.

Inhibitor Therapeutics Inc (OTC-INTI) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Inhibitor Therapeutics Inc is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Inhibitor Therapeutics Inc is 44.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)